<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Maze Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Maze Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:09:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/maze-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683595ce78dffbe2df1044ca.webp</url>
<title>Maze Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Maze Therapeutics Announces $150 Million Registered Offering</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-dollar150-million-registered-offering</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-dollar150-million-registered-offering</guid>
<pubDate>Wed, 22 Apr 2026 04:09:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price</description>
</item>
<item>
<title>Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement</description>
</item>
<item>
<title>Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-positive-topline-data-from-phase-2-horizon-trial-of-mze829-demonstrating-the-first-clinical-proof-of-concept-in-patients-with-broad-apol1-mediated-kidney-disease</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-positive-topline-data-from-phase-2-horizon-trial-of-mze829-demonstrating-the-first-clinical-proof-of-concept-in-patients-with-broad-apol1-mediated-kidney-disease</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction</description>
</item>
<item>
<title>Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-guggenheim-emerging-120000517</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-guggenheim-emerging-120000517</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 3:00 p.m. ET. A live webcast of the event will be available in the</description>
</item>
<item>
<title>Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-present-additional-data-highlighting-advancement-mze829-and-mze782</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-present-additional-data-highlighting-advancement-mze829-and-mze782</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and</description>
</item>
<item>
<title>Maze Therapeutics to Participate in Four Upcoming Investor Conferences</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-four-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-four-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-appoints-industry-veteran-herve-hoppenot-chairman-board-directors</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-appoints-industry-veteran-herve-hoppenot-chairman-board-directors</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage</description>
</item>
<item>
<title>Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-oversubscribed-1500-million-private-placement-2025-09-11</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-oversubscribed-1500-million-private-placement-2025-09-11</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-positive-first-human-results-phase-1-trial-mze782</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-announces-positive-first-human-results-phase-1-trial-mze782</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU</description>
</item>
<item>
<title>Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-appoints-misbah-tahir-chief-financial-officer-2025-09-02</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-appoints-misbah-tahir-chief-financial-officer-2025-09-02</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025</description>
</item>
<item>
<title>Maze Therapeutics to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-two-upcoming-investor-conferences-2025-07-10</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-two-upcoming-investor-conferences-2025-07-10</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-jefferies-2025-global-healthcare-conference-2025-05-29</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-jefferies-2025-global-healthcare-conference-2025-05-29</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-first-quarter-2025-financial-results-and-reiterates</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-first-quarter-2025-financial-results-and-reiterates</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing;</description>
</item>
<item>
<title>Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-3rd-annual-hc-wainwright-bioconnect-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-participate-3rd-annual-hc-wainwright-bioconnect-investor-conference</guid>
<pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Mon, 31 Mar 2025 04:00:00 GMT</pubDate>
<description>MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial</description>
</item>
<item>
<title>Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease</title>
<link>https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-doses-first-patient-phase-2-horizon-clinical-trial-evaluating</link>
<guid isPermaLink="true">https://6ix.com/company/maze-therapeutics-inc-common-stock/news/maze-therapeutics-doses-first-patient-phase-2-horizon-clinical-trial-evaluating</guid>
<pubDate>Fri, 07 Feb 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing</description>
</item>
</channel>
</rss>